Immunotherapy plus chemotherapy for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III non-small cell lung cancer that cannot be removed with initial surgery.
- You have not had any previous cancer treatment for this lung cancer.
- A biopsy confirmed the cancer has spread to lymph nodes in the middle of the chest (N2).
- You are physically active and able to do daily tasks (ECOG score 0-1).
- Your blood counts and organ function (liver, kidneys, lungs) meet minimum levels.
- You do not have an active infection such as hepatitis B or C, or uncontrolled autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and chemotherapy) given before and after surgery to treat stage II-IIIB non-small cell lung cancer. The goal is to see if this approach can improve outcomes for patients whose cancer can be removed surgically.
This trial tests a combination of two immunotherapy drugs plus chemotherapy to shrink lung tumors so they can be removed with surgery. The goal is to give patients with stage III unresectable non-small cell lung cancer a chance at surgery and a better outcome.
This study tests a new approach: giving an immunotherapy drug (tislelizumab) plus chemotherapy before surgery or radiation for advanced lung cancer that has spread to chest lymph nodes. The goal is to shrink the cancer first, then remove or treat it, to improve chances of long-term control.
This trial tests combining the drug tislelizumab with chemotherapy for people with stage III non-small cell lung cancer that hasn't been treated yet. It aims to see if this combination can shrink or control the cancer better.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Hear when a new NSCLC, Stage IIIA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.